Harrow, Inc. (NASDAQ:HROW) Given Average Recommendation of “Buy” by Brokerages

Shares of Harrow, Inc. (NASDAQ:HROW) have earned an average rating of “Buy” from the six analysts that are presently covering the company, MarketBeat reports. Six research analysts have rated the stock with a buy rating. The average 1-year target price among brokerages that have issued a report on the stock in the last year is $61.40.

HROW has been the subject of a number of research reports. BTIG Research initiated coverage on shares of Harrow in a research report on Thursday, June 12th. They set a “buy” rating and a $62.00 price target for the company. HC Wainwright lifted their price objective on Harrow from $57.00 to $60.00 and gave the stock a “buy” rating in a research report on Monday, May 12th. William Blair initiated coverage on Harrow in a research report on Tuesday, June 10th. They set an “outperform” rating for the company. Finally, B. Riley cut their price objective on Harrow from $69.00 to $65.00 and set a “buy” rating for the company in a research report on Tuesday, April 1st.

Institutional Investors Weigh In On Harrow

Several hedge funds have recently made changes to their positions in HROW. GF Fund Management CO. LTD. acquired a new stake in shares of Harrow during the fourth quarter worth $25,000. Quarry LP acquired a new stake in shares of Harrow during the first quarter worth $32,000. Tower Research Capital LLC TRC boosted its holdings in shares of Harrow by 769.5% during the fourth quarter. Tower Research Capital LLC TRC now owns 1,652 shares of the company’s stock worth $55,000 after purchasing an additional 1,462 shares during the last quarter. Aquatic Capital Management LLC acquired a new stake in shares of Harrow during the fourth quarter worth $78,000. Finally, State of Wyoming acquired a new stake in shares of Harrow during the first quarter worth $97,000. Institutional investors and hedge funds own 72.76% of the company’s stock.

Harrow Price Performance

HROW stock opened at $31.78 on Monday. The firm has a 50 day moving average of $28.32 and a 200-day moving average of $28.82. Harrow has a 12-month low of $20.85 and a 12-month high of $59.23. The company has a current ratio of 0.91, a quick ratio of 0.85 and a debt-to-equity ratio of 2.01. The company has a market cap of $1.17 billion, a price-to-earnings ratio of -56.75 and a beta of 0.41.

Harrow (NASDAQ:HROW) last posted its quarterly earnings results on Thursday, May 8th. The company reported ($0.38) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.02 by ($0.40). Harrow had a negative net margin of 10.19% and a negative return on equity of 25.01%. The company had revenue of $47.83 million for the quarter, compared to analyst estimates of $57.00 million. As a group, equities analysts expect that Harrow will post -0.53 EPS for the current fiscal year.

About Harrow

Harrow, Inc operates as an ophthalmic-focused healthcare company. The company owns ImprimisRx, an ophthalmology outsourcing and pharmaceutical compounding business. The company was formerly known as Imprimis Pharmaceuticals, Inc and changed its name to Harrow Health, Inc in December 2018. Harrow Health, Inc was incorporated in 2006 and is headquartered in Nashville, Tennessee.